ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues

Revenues from collaboration and license agreements for the three months ended March 31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March 31, 2023 were as follows:


	Three Months Ended March 31,
		2023
Biogen MA, Inc.		84	%
Kite Pharma, Inc.		8	%

Novartis Institutes for BioMedical Research, Inc.		6	%
Other license agreements		2	%

Schedule of Cash and Cash Equivalents

A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):


	March 31, 2024		December 31, 2023		March 31, 2023		December 31, 2022
Cash and cash equivalents	$	54,417	$	45,204	$	78,241	$	100,444
Current restricted cash	916		—		—		—
Non-current restricted cash	—		1,500		1,500		1,500
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows	$	55,333	$	46,704	$	79,741	$	101,944

Restrictions on Cash and Cash Equivalents


	March 31, 2024		December 31, 2023		March 31, 2023		December 31, 2022
Cash and cash equivalents	$	54,417	$	45,204	$	78,241	$	100,444
Current restricted cash	916		—		—		—
Non-current restricted cash	—		1,500		1,500		1,500
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows	$	55,333	$	46,704	$	79,741	$	101,944